Skip to content

Renal pelvis and ureter cancer

The cancer that grows in the lining of the kidney and ureter, when the kidney can be spared and how the surgery works.

Dr. Petronio Melo, urologistA reference in robotic surgery for kidney and bladder tumors
CRM-SP 157.598 · RQE 70.275
Reviewed by Dr. Petronio Melo on November 13, 2026
Book a consultation
Drawing of the kidneys, ureters and bladder with a tumor in the pelvis of one kidney and in the ureter on the same side, highlighting what the surgery removes, the kidney, the whole ureter and the bladder cuff around it
On this page

Quick answer

Cancer of the renal pelvis and ureter grows from the urothelium, the inner lining of the urinary tract, the same lining as the bladder. It is rare: 5% to 10% of urothelial cancers.1 The most common sign is blood in the urine.2 For low-risk tumors, the European guideline recommends sparing the kidney. For high-risk tumors without metastasis, the standard treatment is nephroureterectomy, which removes the kidney, the ureter and the bladder cuff around it, by an open, laparoscopic or robotic approach.4

What it is

Urine leaves the kidney through a cavity called the renal pelvis and travels down to the bladder through the ureter. This pathway is lined on the inside by the urothelium, the same lining as the bladder. A cancer that starts there is called upper tract urothelial carcinoma.1

It accounts for 5% to 10% of urothelial cancers, with about 2 new cases per 100,000 people per year in Western countries. It is most common between ages 70 and 90 and twice as common in men. Tumors of the renal pelvis are about twice as frequent as those of the ureter, and 10% to 20% of people have more than one tumor.1

It is different from the more common kidney cancer, which grows from the kidney tissue. Because it starts in the same lining, it is closer to bladder cancer.

Risk factors

Smoking raises the risk 2.5 to 7 times. Aristolochic acid, a substance found in some plants, is the other factor with strong evidence.1

This cancer is also part of Lynch syndrome, an inherited condition that raises the risk of bowel cancer and cancer of other organs. The European guideline recommends asking every patient with this cancer about their family history, to identify who may have the syndrome.1

Symptoms and tests

The most common symptom is blood in the urine. Flank pain occurs in 20% to 32% of cases, when a clot or the tumor itself blocks the flow of urine.2

The European guideline recommends:2

  • CT urography, a contrast CT that shows the whole urinary tract, for diagnosis and staging. MRI is used when CT is not possible.
  • Cystoscopy, to rule out a bladder tumor at the same time.
  • Urine cytology, which looks for tumor cells.
  • Chest CT for high-risk tumors.
  • Ureteroscopy, when imaging and cytology are not enough for the diagnosis or to define the risk.

Ureteroscopy passes a thin scope through the urethra and bladder up to the ureter and kidney, so the tumor can be seen and biopsied. In review studies, biopsy during ureteroscopy raised the risk of a new bladder tumor after surgery.2

Low and high risk

Treatment depends on the risk that the tumor is invasive. Grade, seen on the biopsy, is the most important factor.3 A low-grade, small, single tumor with no signs of invasion on CT urography tends to be low risk. A high-grade tumor, or one with signs of invasion on CT, is high risk.3

Size, more than one tumor and a swollen kidney are weaker factors. On their own, they are not enough to define the risk. When they appear with a low-grade tumor, the choice between sparing and removing the kidney is made together with the patient.3

When the kidney can be spared

For low-risk tumors, the European guideline recommends sparing the kidney as the first option, because survival is similar to nephroureterectomy, without losing a kidney.4

  • Endoscopic treatment. A laser destroys the tumor from inside, through ureteroscopy. It requires a second ureteroscopy within 8 weeks and close follow-up, because 1 in 2 patients has the tumor come back on the same side within 2 years.4
  • Distal ureterectomy. Removes only the lower end of the ureter, for tumors in that area, and reconnects the ureter to the bladder.4

In some high-risk cases, such as people with a single kidney or poor kidney function, sparing the kidney can be discussed case by case, despite the higher risk of progression.4

How nephroureterectomy works

For high-risk tumors without metastasis, radical nephroureterectomy is the standard treatment. It removes in one piece the kidney, the whole ureter and a small cuff of bladder around the ureter's opening. The cuff comes out too because the tumor often comes back in that area and in the bladder.4

The operation can be open, laparoscopic or robotic. Cancer outcomes were similar across the three approaches, and the minimally invasive ones led to fewer complications and a shorter hospital stay.4 The guideline also recommends removing the regional lymph nodes, following a map based on the side and level of the tumor.4

The guideline recommends discussing every suspected case at a meeting with other specialists.4

After surgery

When the pathology shows a tumor that invades the muscle or beyond, or lymph nodes with cancer, the guideline recommends offering platinum-based chemotherapy.4 In the POUT trial, with 261 patients, 71% of those who had chemotherapy were free of disease at 3 years, compared with 50% of those who were only monitored.4,6 Immunotherapy can be discussed with people who cannot have or do not want chemotherapy, in specific situations.4

Follow-up

About 30% of patients develop a new bladder tumor after treatment, and 2% to 5% develop a tumor in the other kidney or ureter.1 That is why follow-up checks the bladder and the rest of the urinary tract.5

After nephroureterectomyWhat the European guideline suggests
Low riskCystoscopy at 3 months, again 9 months later and then once a year, for 5 years5
High riskCystoscopy and cytology at 3 months and then every 3 or 6 months for the first 2 years; CT urography and chest CT every 6 months for 2 years and then once a year5

How I approach it

I review the images, the cytology and the biopsy, when there is one, and talk with the patient about sparing the kidney or having a nephroureterectomy. When surgery is indicated, it can be done robotically. In my practice, the hospital stay is 1 to 2 days, and the catheter stays for 3 to 5 days.

When to see a urologist

  • If you have seen blood in your urine, even once
  • If a CT or ultrasound showed a lesion in the renal pelvis or ureter, or a swollen kidney without a stone
  • If urine cytology was abnormal and the bladder looks normal
  • If you have had bladder cancer and now have blood in the urine or flank pain
  • If several relatives have had bowel, uterine or urinary tract cancer

Frequently asked questions

What is a nephroureterectomy?

It is the operation that removes the kidney, the whole ureter and a small cuff of bladder around the ureter's opening, all in one piece. It is the standard treatment for high-risk cancer of the renal pelvis and ureter without metastasis.4

Is renal pelvis cancer the same as kidney cancer?

No. The most common kidney cancer grows from the kidney tissue. Renal pelvis cancer grows from the inner lining of the urinary tract, the urothelium, the same lining as the bladder, and it is treated differently.1

Does the kidney always have to be removed?

No. For low-risk tumors, the European guideline recommends sparing the kidney, with endoscopic treatment or removal of only the lower end of the ureter. Nephroureterectomy is for high-risk tumors.4

Can nephroureterectomy be done robotically?

Yes. The operation can be open, laparoscopic or robotic, with similar cancer outcomes. Minimally invasive approaches lead to fewer complications and a shorter hospital stay.4

Why are cystoscopies needed after surgery?

Because about 30% of patients develop a new tumor in the bladder after treatment. Regular cystoscopy finds it early.1,5

References

  1. EAU Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma. European Association of Urology; 2026. Epidemiology, aetiology and pathology chapter. EAU
  2. EAU Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma. European Association of Urology; 2026. Diagnosis chapter. EAU
  3. EAU Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma. European Association of Urology; 2026. Risk stratification chapter. EAU
  4. EAU Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma. European Association of Urology; 2026. Disease management chapter. EAU
  5. EAU Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma. European Association of Urology; 2026. Follow-up chapter. EAU
  6. Birtle A, Johnson M, Chester J, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet. 2020;395(10232):1268-1277. PubMed

Would you like to talk about your case?

In the consultation, I go over your tests and your priorities.

Book a consultation

Related guides